Growth Hormone (Somatropin) vs Testosterone Propionate

Mechanism

Recombinant human growth hormone (rhGH/somatropin) is a 191-amino acid protein identical to endogenous GH. It binds the GH receptor (GHR), a type I cytokine receptor, activating the JAK2-STAT5 signaling cascade that drives hepatic IGF-1 production — the primary mediator of GH's anabolic effects. GH directly stimulates lipolysis via hormone-sensitive lipase (HSL) activation and inhibits lipogenesis. It promotes chondrocyte proliferation, collagen synthesis, and linear bone growth. GH also enhances protein synthesis through mTOR pathway activation and improves nitrogen balance. Pulsatile secretion patterns are important — continuous GH exposure preferentially drives IGF-1, while pulsatile release favors direct lipolytic effects.

Standard Dosing

Research indicates 1-2 IU/day (0.33-0.67 mg/day) subcutaneously for anti-aging and body composition. Clinical GHD replacement: 0.2-0.6 mg/day titrated to IGF-1 levels.

Timing

Inject subcutaneously in the morning fasted (mimics physiological pulse) or before bed (mimics nocturnal secretion). Rotate injection sites (abdomen, thigh, deltoid). If using with insulin, separate GH injection by several hours. Fasted-state injection preferred for maximal lipolytic effect.

Cycle Duration

Long-term (6-12+ months) for body composition benefits. Clinical GHD replacement is indefinite. Minimum 3-6 months to assess efficacy.

Side Effects

• Fluid retention and edema (dose-dependent, typically resolves in 2-4 weeks)
• Carpal tunnel syndrome and joint pain
• Insulin resistance and elevated fasting glucose
• Headache
• Numbness and paresthesias
• Potential increased cancer risk with chronic supraphysiological IGF-1 levels
• Gynecomastia
• Acromegalic features with long-term excessive dosing (jaw growth, digit enlargement)

Contraindications

• Active malignancy (GH/IGF-1 promotes cell proliferation)
• Active proliferative or preproliferative diabetic retinopathy
• Acute critical illness (GH increased mortality in ICU patients)
• Active intracranial lesion or tumor
• Prader-Willi syndrome with severe obesity or respiratory impairment
• Closed epiphyses (for linear growth indication only)

Best Stacking Partners

Mechanism

Testosterone propionate is a short-acting esterified testosterone with a propionic acid ester, resulting in a half-life of approximately 0.8-1.5 days. Rapid hydrolysis by serum esterases produces a sharp testosterone spike followed by quick clearance. It activates the same androgen receptor-mediated genomic and non-genomic pathways as longer esters, but the pharmacokinetic profile demands frequent dosing. The short duration makes it useful for rapid onset situations and fine-tuned dose titration.

Standard Dosing

Research indicates 25-50 mg administered every other day or 50-100 mg every 2-3 days via intramuscular or subcutaneous injection.

Timing

Every-other-day or daily injection required due to short half-life. Rotate injection sites to minimize tissue irritation.

Cycle Duration

Short cycles (4-8 weeks) or as bridge therapy. Not typically used for long-term TRT due to injection frequency burden.

Side Effects

• Injection site pain and irritation (higher incidence than longer esters)
• Significant peak-trough mood and energy fluctuations
• Acne
• Polycythemia
• Gynecomastia (less common due to lower aromatization window)

Contraindications

• Prostate cancer or elevated PSA
• Polycythemia (hematocrit >54%)
• Untreated sleep apnea
• Pregnancy exposure risk
• Allergy to carrier oil components

Best Stacking Partners